SEPARATION AND RELEASE AGREEMENTSeparation and Release Agreement • February 28th, 2020 • Heska Corp • In vitro & in vivo diagnostic substances • Colorado
This Separation and Release Agreement (the “Agreement”) is made between (i) Steve Asakowicz (“Employee”) and (ii) Heska Corporation (the “Company”). Employee and the Company are referred to collectively as the “Parties” and individually as a “Party.”
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 28th, 2020 • Heska Corp • In vitro & in vivo diagnostic substances • Delaware
This Securities Purchase Agreement (this “Agreement”) is dated as of January 12, 2020 by and among HESKA CORPORATION, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
THIRD AMENDMENT TO CLINICAL CHEMISTRY ANALYZER AGREEMENTClinical Chemistry Analyzer Agreement • February 28th, 2020 • Heska Corp • In vitro & in vivo diagnostic substances
This Third Amendment to Clinical Chemistry Analyzer Agreement (the “Amendment”), entered into as of August 27th, 2019, modifies that certain Clinical Chemistry Analyzer Agreement between FUJIFILM Corporation and Heska Corporation, dated January 30, 2007, including its amendments by the First Amendment to Clinical Chemistry Analyzer Agreement dated April 1st, 2014 and the Second Amendment to Clinical Chemistry Analyzer Agreement dated April 1st, 2015 (collectively, “Original Agreement”). Capitalized terms not otherwise defined have the meanings ascribed to them in the Original Agreement. In the event of any conflict between the terms and conditions of the Original Agreement and this Amendment, the terms and conditions of this Amendment shall control. The headings in this Amendment are included for purposes of convenience only and shall not affect the construction or interpretation of its provisions.
